Establishment of Ph. Eur. Bordetella pertussis mouse antiserum Biological Reference Preparation batches 2, 3 and 4.

Autor: Morgeaux, S., Chagnaud, P., Variot, P., Le Tallec, D., Behr-Gross, M.-E.

Publikováno v: Pharmeuropa Bio & Scientific Notes; Dec2020, p161-202, 42p

Establishment of detection antibodies BRRs batch 5 for in vitro potency assay of hepatitis A vaccines by ELISA.

Autor: MORGEAUX, S., KOY, A., MANNIAM, I., REGOURD, E., VARIOT, P., MILNE, C.

Publikováno v: Pharmeuropa Bio & Scientific Notes; 2019, p1-10, 10p

Evaluation of the immune status of dogs vaccinated against rabies by an enzyme-linked immunosorbent assay using crude preparations of insect cells infected with a recombinant baculovirus encoding the rabies virus glycoprotein gene.

Autor: Santosh, A. K.¹ (AUTHOR), Kumar, Deepak² (AUTHOR), Kaur, Charanpreet³ (AUTHOR), Gupta, Priya^3,4 (AUTHOR), Jasmeen, Pagala^3,4 (AUTHOR), Dilip, L.¹ (AUTHOR), Kavitha, G.¹ (AUTHOR), Basagoudanavar, Suresh⁵ (AUTHOR), Hosamani, Madhusudan⁵ (AUTHOR), Balamurugan, V.⁶ (AUTHOR), Sharada, R.¹ (AUTHOR), Rathnamma, D.¹ (AUTHOR), Sunil, K. M.¹ (AUTHOR), Hegde, Nagendra R.^3,4 (AUTHOR) hegde@niab.org.in, Isloor, Shrikrishna¹ (AUTHOR) kisloor@gmail.com

Publikováno v: PLoS ONE. 12/3/2024, Vol. 19 Issue 12, p1-18. 18p.

Establishment of hepatitis A detection antibodies set BRR batch 3 for antigen content determination by ELISA.

Autor: Morgeaux, S., Manniam, I., Variot, P., Daas, A., Costanzo, A.

Publikováno v: Pharmeuropa Bio & Scientific Notes; 2015, p235-245, 11p

Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study.

Autor: Morgeaux S; Agence Nationale de Sécurité du Médicament et des Produits de Santé, Laboratory Controls Division, Batch Release and Marketing Surveillance of Biological Products Department, 312 Avenue Jean Jaurès, F-69007 Lyon, France., Poirier B; Independent Statistical Expert, 207 L'Ove, 69700 Chassagny, France., Ragan CI; European Partnership for Alternative Approaches to Animal Testing, Brussels, Belgium. Electronic address: ian.ragan1@btinternet.com., Wilkinson D; Division of Virology, National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK., Arabin U; GSK Vaccines GmbH, Emil-von-Behring-Straβe 76, 35041 Marburg, Germany., Guinet-Morlot F; Sanofi-Pasteur, 1541 av. Marcel Mérieux, 69280 Marcy L'Etoile, France., Levis R; Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA., Meyer H; Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany., Riou P; Sanofi-Pasteur, 1541 av. Marcel Mérieux, 69280 Marcy L'Etoile, France., Shaid S; GSK Vaccines GmbH, Emil-von-Behring-Straβe 76, 35041 Marburg, Germany., Volokhov D; Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA., Tordo N; Unité Stratégies Antivirales, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France; Institut Pasteur de Guinée, Conakry, Guinea., Chapsal JM; Independent Expert, 195 Traverse des Verdelières, 69380 Charnay, France.

Publikováno v: Vaccine [Vaccine] 2017 Feb 07; Vol. 35 (6), pp. 966-971. Date of Electronic Publication: 2017 Jan 09.